Integra LifeSciences Holdings Co. (NASDAQ:IART) to Post Q4 2023 Earnings of $0.93 Per Share, Zacks Research Forecasts

Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating) – Research analysts at Zacks Research cut their Q4 2023 earnings per share estimates for shares of Integra LifeSciences in a research report issued to clients and investors on Monday, September 19th. Zacks Research analyst U. Biswas now expects that the life sciences company will post earnings of $0.93 per share for the quarter, down from their previous forecast of $0.94. The consensus estimate for Integra LifeSciences’ current full-year earnings is $3.16 per share.

Integra LifeSciences (NASDAQ:IARTGet Rating) last issued its quarterly earnings data on Wednesday, July 27th. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.80 by $0.02. The company had revenue of $397.82 million during the quarter, compared to analysts’ expectations of $394.54 million. Integra LifeSciences had a return on equity of 16.72% and a net margin of 10.61%.

IART has been the topic of several other reports. Morgan Stanley reduced their target price on Integra LifeSciences from $59.00 to $58.00 and set an “equal weight” rating on the stock in a report on Thursday, August 25th. Piper Sandler decreased their target price on Integra LifeSciences from $55.00 to $50.00 in a report on Wednesday, August 24th. TheStreet cut Integra LifeSciences from a “b-” rating to a “c+” rating in a report on Friday, July 8th. Finally, Truist Financial decreased their price objective on shares of Integra LifeSciences from $70.00 to $56.00 and set a “hold” rating on the stock in a report on Wednesday, July 20th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Integra LifeSciences currently has an average rating of “Hold” and a consensus target price of $65.43.

Integra LifeSciences Price Performance

Shares of Integra LifeSciences stock opened at $43.39 on Thursday. Integra LifeSciences has a 1-year low of $43.07 and a 1-year high of $74.98. The firm’s 50-day moving average price is $51.77 and its two-hundred day moving average price is $57.34. The company has a current ratio of 3.85, a quick ratio of 2.76 and a debt-to-equity ratio of 0.90. The stock has a market capitalization of $3.62 billion, a price-to-earnings ratio of 22.03, a P/E/G ratio of 1.47 and a beta of 1.12.

Insiders Place Their Bets

In related news, EVP Lisa Evoli sold 1,165 shares of the business’s stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $55.81, for a total transaction of $65,018.65. Following the completion of the sale, the executive vice president now directly owns 17,997 shares of the company’s stock, valued at $1,004,412.57. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director Raymond G. Murphy sold 8,000 shares of the business’s stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $55.78, for a total transaction of $446,240.00. Following the completion of the transaction, the director now directly owns 40,825 shares in the company, valued at approximately $2,277,218.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Lisa Evoli sold 1,165 shares of the company’s stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of $55.81, for a total value of $65,018.65. Following the completion of the sale, the executive vice president now directly owns 17,997 shares of the company’s stock, valued at $1,004,412.57. The disclosure for this sale can be found here. In the last three months, insiders sold 9,602 shares of company stock valued at $536,067. 4.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of IART. Goldman Sachs Group Inc. grew its holdings in shares of Integra LifeSciences by 73.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,482,718 shares of the life sciences company’s stock valued at $99,327,000 after buying an additional 629,202 shares during the period. Cubist Systematic Strategies LLC grew its stake in Integra LifeSciences by 381.0% in the second quarter. Cubist Systematic Strategies LLC now owns 312,861 shares of the life sciences company’s stock valued at $16,904,000 after acquiring an additional 247,813 shares during the period. Alliancebernstein L.P. increased its holdings in shares of Integra LifeSciences by 11.0% in the fourth quarter. Alliancebernstein L.P. now owns 2,329,360 shares of the life sciences company’s stock worth $156,044,000 after acquiring an additional 231,383 shares in the last quarter. Leeward Investments LLC MA bought a new position in shares of Integra LifeSciences during the 1st quarter valued at about $14,479,000. Finally, Franklin Resources Inc. acquired a new position in shares of Integra LifeSciences in the 2nd quarter valued at approximately $10,777,000. Institutional investors and hedge funds own 87.33% of the company’s stock.

Integra LifeSciences Company Profile

(Get Rating)

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.

Read More

Earnings History and Estimates for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.